IUCT-Oncopole Becomes First French Hospital to Adopt MSK-ACCESS® powered with SOPHiA DDM™
The French comprehensive cancer center implements liquid biopsy test to further its cancer diagnostics and research Boston, MA and Rolle, Switzerland, June 19, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in...
SOPHiA GENETICS Announces Kepler Uniklinikum is Live on SOPHiA DDM™ Platform
The Hospital will use SOPHiA DDM™ to enhance its testing and research of blood cancers Boston, MA and Rolle, Switzerland, June 13, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, today...
SOPHiA GENETICS Launches Global Consortium, SOPHiA UNITY, to Accelerate Cancer Research, Drug Development, and Data-Driven Patient Care
New collective intelligence network to enable the most advanced research in oncology in support of precision medicine BOSTON and ROLLE, Switzerland, May 30, 2024– SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in...
SOPHiA GENETICS to Launch New Whole Genome Sequencing Capabilities
In collaboration with Microsoft and NVIDIA, SOPHiA GENETICS is developing a comprehensive whole genome analytical solution Boston, US and Rolle, Switzerland, May 29, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global...
SOPHiA GENETICS Announces Instituto Mario Penna as New Customer
The Hospital will enhance its testing and research of blood cancers with the SOPHiA DDM™ Platform Boston, MA and Rolle, Switzerland, May 20, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven...
AMP Europe
SOPHiA GENETICS is excited to be a part of the Association for Molecular Pathology (AMP) 2024 Europe Congress held in Madrid, Spain from June 24th - 26th.You will have the chance to chat with our experts at booth #12 and demo the universal SOPHiA DDM™...
Klinikum Klagenfurt am Wörthersee is Live with SOPHiA GENETICS
The SOPHiA DDM™ Platform will help broaden the hospital’s cancer testing and diagnostic capabilities Boston, MA and Rolle, Switzerland, May 16, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today...
ESHG Event
We can’t wait to meet you at booth #348, June 1-3. Meet our team to learn how SOPHiA GENETICS can help turn complex genetic data into life-changing insights. We will also be hosting a talk on Monday, June 3 from 8:30-10:00 am. Don't miss it!...
Customer Spotlight: Katherine Lafferty at Broad Clinical Labs
We recently sat down to talk with Katherine Lafferty, MS, CGC about how Alamut™ Visual Plus helps her overcome the variant interpretation challenges she encounters in her work as a variant analyst. Read our discussion.
SOPHiA GENETICS Reports First Quarter 2024 Results
Consistent Operational Execution; Robust New Business Momentum; Guidance Reaffirmed BOSTON, United States and ROLLE, Switzerland, May 7, 2024 — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported...
SOPHiA GENETICS to Present at the 2024 RBC Capital Markets Global Healthcare Conference
BOSTON, United States and ROLLE, Switzerland, April 30, 2024 — SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced that Chief Financial Officer and Chief Operating Officer, Ross Muken, will present at the 2024 RBC...
SOPHiA GENETICS to Announce Financial Results for First Quarter 2024 on May 7, 2024
BOSTON, United States and ROLLE, Switzerland, April 23, 2024 — SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter of fiscal year 2024 before U.S....
SOPHiA GENETICS Announces Syndicate Bio as First Liquid Biopsy Customer in Africa
Syndicate Bio to implement new liquid biopsy offering to advance cancer diagnostics throughout Africa Boston, MA and Rolle, Switzerland, April 23, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in...
SOPHiA GENETICS Announces Unilabs is using its AI Technology to Detect Homologous Recombination Deficiency (HRD)
European-based Unilabs has deployed the SOPHiA DDM™ Platform across its network in Switzerland to support cancer diagnostics and treatment Boston, MA and Rolle, Switzerland, April 17, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a...
